Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently updated its clinical study titled ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

Dec 12 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative ...

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Shortly after, Novo Nordisk's CEO Mike Doustdar signaled the company is "all in" on the forthcoming launch of oral semaglutide, emphasizing robust supply readiness ahead of the anticipated year-end ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Lilly's next-generation obesity shot is starting to look like the company's most powerful swing yet in a market investors expect to reshape global healthcare economics. After releasing late-stage data ...

Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted ...

Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.